China vaccine stocks rebound as Merkel opposes patent waiver


FILE PHOTO: A medical worker prepares a dose of the "Comirnaty" Pfizer-BioNTech COVID-19 vaccine inside the exhibition palace transformed into a vaccination center in Nice as part of the coronavirus disease (COVID-19) vaccination campaign in France, April 29, 2021. REUTERS/Eric Gaillard

SHARES of Covid-19 vaccine developers in Asia got some relief after the German Chancellor rejected a U.S. proposal to waive patent protections for coronavirus shots.

Chinese vaccine makers rebounded after slumping on Thursday following the initial news that the U.S. would support discussions for a waiver of the rights to develop vaccines. The Biden administration’s plan would create "severe complications” for the production of vaccines, a German government spokeswoman said Thursday in an email.

Limited time offer:
Just RM5 per month.

Monthly Plan

RM13.90/month
RM5/month

Billed as RM5/month for the 1st 6 months then RM13.90 thereafters.

Annual Plan

RM12.33/month

Billed as RM148.00/year

1 month

Free Trial

For new subscribers only


Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
   

Next In Business News

Powering on data centres
Medical insurance premiums on the rise
Blackstone, KKR mortgage REITs stung by office debt challenges
Making scents of success
Tesla’s plan for affordable cars takes page from Detroit rivals
Sapura Energy takes a step to turn the tide
Are there too many GPs and is the healthcare system overwhelmed?
Kelington to reap the benefits of a diversified business strategy
Investors brace for 5% Treasury yields
Singapore’s growth trajectory remains intact

Others Also Read